{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:23:40Z","timestamp":1785803020267,"version":"3.56.0"},"reference-count":80,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100005326","name":"Yale University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Infectious Disease Clinics of North America"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.idc.2023.12.002","type":"journal-article","created":{"date-parts":[[2024,1,26]],"date-time":"2024-01-26T01:24:32Z","timestamp":1706232272000},"page":"149-162","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Novel Approaches to Multidrug-Resistant Infections in Cystic Fibrosis"],"prefix":"10.1016","volume":"38","author":[{"given":"Thomas S.","family":"Murray","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gail","family":"Stanley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan L.","family":"Koff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.idc.2023.12.002_bib1","unstructured":"Centers for disease control and prevention https:\/\/www.cdc.gov\/infectioncontrol\/guidelines\/mdro\/. updated February 2017 Accessed July 7, 2022."},{"key":"10.1016\/j.idc.2023.12.002_bib2","unstructured":"Cystic Fibrosis Foundation Patient Registry 2020 Annual Data Report Bethesda, Maryland \u00a92021 Cystic Fibrosis Foundation."},{"issue":"3","key":"10.1016\/j.idc.2023.12.002_bib3","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.jcf.2019.07.008","article-title":"The impact of CFTR modulator therapies on CF airway microbiology","volume":"19","author":"Rogers","year":"2020","journal-title":"J\u00a0Cyst Fibros"},{"issue":"Suppl 3","key":"10.1016\/j.idc.2023.12.002_bib4","first-page":"S18","article-title":"Improving outcomes of infections in cystic fibrosis in the era of CFTR modulator therapy","volume":"54","author":"Saiman","year":"2019","journal-title":"Pediatr Pulmonol"},{"issue":"12","key":"10.1016\/j.idc.2023.12.002_bib5","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1164\/rccm.201609-1954OC","article-title":"Restoring Cystic Fibrosis Transmembrane Conductance Regulator Function Reduces Airway Bacteria and Inflammation in People with Cystic Fibrosis and Chronic Lung Infections","volume":"195","author":"Hisert","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.idc.2023.12.002_bib6","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1513\/AnnalsATS.201907-493OC","article-title":"Changes in Airway Microbiome and Inflammation with Ivacaftor Treatment in Patients with Cystic Fibrosis and the G551D Mutation","volume":"17","author":"Harris","year":"2020","journal-title":"Ann Am Thorac Soc"},{"issue":"7","key":"10.1016\/j.idc.2023.12.002_bib7","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1002\/ppul.25353","article-title":"State of the art in cystic fibrosis pharmacology optimization of antimicrobials in the treatment of cystic fibrosis pulmonary exacerbations: III. Executive summary","volume":"56","author":"Epps","year":"2021","journal-title":"Pediatr Pulmonol"},{"issue":"3","key":"10.1016\/j.idc.2023.12.002_bib8","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD001021.pub3","article-title":"Inhaled anti-pseudomonal antibiotics for long-term therapy in cystic fibrosis","author":"Smith","year":"2018","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"10","key":"10.1016\/j.idc.2023.12.002_bib9","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1016\/j.clinthera.2016.08.014","article-title":"Comparison of Inhaled Antibiotics for the Treatment of Chronic Pseudomonas aeruginosa Lung Infection in Patients With Cystic Fibrosis: Systematic Literature Review and Network Meta-analysis","volume":"38","author":"Elborn","year":"2016","journal-title":"Clin Ther"},{"issue":"3","key":"10.1016\/j.idc.2023.12.002_bib10","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1128\/CMR.00101-15","article-title":"Inhaled Antibiotics for Gram-Negative Respiratory Infections","volume":"29","author":"Wenzler","year":"2016","journal-title":"Clinical microbiology reviews"},{"issue":"1","key":"10.1016\/j.idc.2023.12.002_bib11","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00115-20","article-title":"New \u03b2-Lactam-\u03b2-Lactamase Inhibitor Combinations","volume":"34","author":"Yahav","year":"2020","journal-title":"Clin Microbiol Rev"},{"issue":"3","key":"10.1016\/j.idc.2023.12.002_bib12","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1136\/adc.77.3.239","article-title":"Enhanced drug metabolism in young children with cystic fibrosis","volume":"77","author":"Parker","year":"1997","journal-title":"Arch Dis Child"},{"issue":"1","key":"10.1016\/j.idc.2023.12.002_bib13","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1177\/106002809302700117","article-title":"Hepatic drug metabolism in cystic fibrosis: recent developments and future directions","volume":"27","author":"Kearns","year":"1993","journal-title":"Ann Pharmacother"},{"issue":"5","key":"10.1016\/j.idc.2023.12.002_bib14","doi-asserted-by":"crossref","first-page":"542","DOI":"10.2165\/00003495-198835050-00004","article-title":"Clinical pharmacology of antibiotics and other drugs in cystic fibrosis","volume":"35","author":"Prandota","year":"1988","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.idc.2023.12.002_bib15","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/ppul.24537","article-title":"State of the art in cystic fibrosis pharmacology-Optimization of antimicrobials in the treatment of cystic fibrosis pulmonary exacerbations: I. Anti-methicillin-resistant Staphylococcus aureus (MRSA) antibiotics","volume":"55","author":"Epps","year":"2020","journal-title":"Pediatr Pulmonol"},{"issue":"6","key":"10.1016\/j.idc.2023.12.002_bib16","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1002\/ppul.25282","article-title":"Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: II. Cephalosporins and penicillins latest update","volume":"56","author":"Epps","year":"2021","journal-title":"Pediatr Pulmonol"},{"issue":"4","key":"10.1016\/j.idc.2023.12.002_bib17","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s40262-020-00981-0","article-title":"Pharmacokinetic and Pharmacodynamic Optimization of Antibiotic Therapy in Cystic Fibrosis Patients: Current Evidences, Gaps in Knowledge and Future Directions","volume":"60","author":"Magreault","year":"2021","journal-title":"Clin Pharmacokinet"},{"issue":"11","key":"10.1016\/j.idc.2023.12.002_bib18","first-page":"723","article-title":"Continuous-infusion antipseudomonal Beta-lactam therapy in patients with cystic fibrosis","volume":"36","author":"Prescott","year":"2011","journal-title":"P\u00a0T"},{"issue":"10","key":"10.1016\/j.idc.2023.12.002_bib19","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00988-17","article-title":"Pharmacokinetic-Pharmacodynamic Target Attainment Analyses To Determine Optimal Dosing of Ceftazidime-Avibactam for the Treatment of Acute Pulmonary Exacerbations in Patients with Cystic Fibrosis","volume":"61","author":"Bensman","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2023.12.002_bib20","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3389\/fped.2020.00173","article-title":"Ceftolozane\/Tazobactam for Treating Children With Exacerbations of Cystic Fibrosis Due to Pseudomonas aeruginosa: A Review of Available Data","volume":"8","author":"Garazzino","year":"2020","journal-title":"Front Pediatr"},{"issue":"7","key":"10.1016\/j.idc.2023.12.002_bib21","doi-asserted-by":"crossref","first-page":"ofy158","DOI":"10.1093\/ofid\/ofy158","article-title":"Vitro Activity of Ceftolozane\/Tazobactam vs Nonfermenting, Gram-Negative Cystic Fibrosis Isolates","volume":"5","author":"Forrester","year":"2018","journal-title":"Open Forum Infect Dis"},{"issue":"2","key":"10.1016\/j.idc.2023.12.002_bib22","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/ppul.24557","article-title":"Ceftazidime-avibactam for the treatment of multidrug resistant Burkholderia cepacia complex in a pediatric cystic fibrosis patient","volume":"55","author":"Nguyen","year":"2020","journal-title":"Pediatr Pulmonol"},{"issue":"2","key":"10.1016\/j.idc.2023.12.002_bib23","doi-asserted-by":"crossref","first-page":"115204","DOI":"10.1016\/j.diagmicrobio.2020.115204","article-title":"In\u00a0vitro activity of ceftolozane-tazobactam and ceftazidime-avibactam against Pseudomonas aeruginosa isolated from patients with cystic fibrosis","volume":"99","author":"Nolan","year":"2021","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"5","key":"10.1016\/j.idc.2023.12.002_bib24","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1093\/jac\/dky558","article-title":"Use of ceftazidime\/avibactam for the treatment of MDR Pseudomonas aeruginosa and Burkholderia cepacia complex infections in cystic fibrosis: a case series","volume":"74","author":"Spoletini","year":"2019","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"3","key":"10.1016\/j.idc.2023.12.002_bib25","doi-asserted-by":"crossref","first-page":"dlab126","DOI":"10.1093\/jacamr\/dlab126","article-title":"Antimicrobial activity of ceftazidime\/avibactam, ceftolozane\/tazobactam and comparator agents against Pseudomonas aeruginosa from cystic fibrosis patients","volume":"3","author":"Sader","year":"2021","journal-title":"JAC Antimicrob Resist"},{"issue":"9","key":"10.1016\/j.idc.2023.12.002_bib26","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00590-18","article-title":"Vitro Susceptibility of Burkholderia cepacia Complex Isolated from Cystic Fibrosis Patients to Ceftazidime-Avibactam and Ceftolozane-Tazobactam","volume":"62","author":"Van Dalem","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.idc.2023.12.002_bib27","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1093\/cid\/cix182","article-title":"Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections: Clinical Effectiveness and Evolution of Resistance","volume":"65","author":"Haidar","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idc.2023.12.002_bib28","doi-asserted-by":"crossref","first-page":"e00830","DOI":"10.1016\/j.idcr.2020.e00830","article-title":"Ceftolozane\/tazobactam for pulmonary exacerbation in a 63-year-old cystic fibrosis patient with renal insufficiency and an elevated MIC to Pseudomonas aeruginosa","volume":"21","author":"Romano","year":"2020","journal-title":"IDCases"},{"key":"10.1016\/j.idc.2023.12.002_bib29","first-page":"8","article-title":"Use of ceftolozane-tazobactam in a cystic fibrosis patient with multidrug-resistant pseudomonas infection and renal insufficiency","volume":"23","author":"Stokem","year":"2018","journal-title":"Respir Med Case Rep"},{"issue":"10","key":"10.1016\/j.idc.2023.12.002_bib30","doi-asserted-by":"crossref","first-page":"e154","DOI":"10.1002\/phar.1825","article-title":"Successful Use of Ceftolozane-Tazobactam to Treat a Pulmonary Exacerbation of Cystic Fibrosis Caused by Multidrug-Resistant Pseudomonas aeruginosa","volume":"36","author":"Vickery","year":"2016","journal-title":"Pharmacotherapy"},{"issue":"9","key":"10.1016\/j.idc.2023.12.002_bib31","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1002\/ppul.25552","article-title":"Optimization of antibiotics for cystic fibrosis pulmonary exacerbations due to highly resistant nonlactose fermenting Gram negative bacilli: Meropenem-vaborbactam and cefiderocol","volume":"56","author":"Belcher","year":"2021","journal-title":"Pediatr Pulmonol"},{"issue":"8","key":"10.1016\/j.idc.2023.12.002_bib32","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.00181-19","article-title":"Switching Partners\": Piperacillin-Avibactam Is a Highly Potent Combination against Multidrug-Resistant Burkholderia cepacia Complex and Burkholderia gladioli Cystic Fibrosis Isolates","volume":"57","author":"Zeiser","year":"2019","journal-title":"J\u00a0Clin Microbiol"},{"issue":"1","key":"10.1016\/j.idc.2023.12.002_bib33","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/s41598-020-57844-8","article-title":"Effect of Amoxicillin in combination with Imipenem-Relebactam against Mycobacterium abscessus","volume":"10","author":"Lopeman","year":"2020","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.idc.2023.12.002_bib34","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s40265-019-1055-2","article-title":"Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli","volume":"79","author":"Zhanel","year":"2019","journal-title":"Drugs"},{"issue":"12","key":"10.1016\/j.idc.2023.12.002_bib35","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1089\/mdr.2020.0602","article-title":"Does Cefiderocol Have a Potential Role in Cystic Fibrosis Pulmonary Exacerbation Management?","volume":"27","author":"Gavioli","year":"2021","journal-title":"Microb Drug Resist"},{"issue":"7","key":"10.1016\/j.idc.2023.12.002_bib36","doi-asserted-by":"crossref","first-page":"e1754","DOI":"10.1093\/cid\/ciaa1847","article-title":"Cefiderocol for the Treatment of Adult and Pediatric Patients With Cystic Fibrosis and Achromobacter xylosoxidans Infections","volume":"73","author":"Warner","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.idc.2023.12.002_bib37","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.jcf.2012.02.006","article-title":"Results of antibiotic susceptibility testing do not influence clinical outcome in children with cystic fibrosis","volume":"11","author":"Hurley","year":"2012","journal-title":"J\u00a0Cyst Fibros"},{"issue":"9484","key":"10.1016\/j.idc.2023.12.002_bib38","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S0140-6736(05)67060-2","article-title":"Combination antibiotic susceptibility testing to treat exacerbations of cystic fibrosis associated with multiresistant bacteria: a randomised, double-blind, controlled clinical trial","volume":"366","author":"Aaron","year":"2005","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.idc.2023.12.002_bib39","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S1473-3099(21)00194-8","article-title":"Widespread cefiderocol heteroresistance in carbapenem-resistant Gram-negative pathogens","volume":"21","author":"Choby","year":"2021","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"10.1016\/j.idc.2023.12.002_bib40","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.ijantimicag.2018.07.027","article-title":"Loss of activity of ceftazidime-avibactam due to MexAB-OprM efflux and overproduction of AmpC cephalosporinase in Pseudomonas aeruginosa isolated from patients suffering from cystic fibrosis","volume":"52","author":"Chalhoub","year":"2018","journal-title":"Int J Antimicrob Agents"},{"issue":"3","key":"10.1016\/j.idc.2023.12.002_bib41","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1016\/j.jcf.2017.10.010","article-title":"Ceftaroline pharmacokinetics and pharmacodynamics in patients with cystic fibrosis","volume":"17","author":"Barsky","year":"2018","journal-title":"J\u00a0Cyst Fibros"},{"issue":"12","key":"10.1016\/j.idc.2023.12.002_bib42","doi-asserted-by":"crossref","first-page":"3337","DOI":"10.1002\/ppul.25029","article-title":"Ceftaroline vs vancomycin for the treatment of acute pulmonary exacerbations in pediatric patients with cystic fibrosis","volume":"55","author":"Branstetter","year":"2020","journal-title":"Pediatr Pulmonol"},{"issue":"2","key":"10.1016\/j.idc.2023.12.002_bib43","first-page":"135","article-title":"Ceftaroline Fosamil for Methicillin-Resistant Staphylococcus aureus Pulmonary Exacerbation in a Pediatric Cystic Fibrosis Patient","volume":"19","author":"Molloy","year":"2014","journal-title":"J\u00a0Pediatr Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.idc.2023.12.002_bib44","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/s42003-020-01313-5","article-title":"Carbapenems drive the collateral resistance to ceftaroline in cystic fibrosis patients with MRSA","volume":"3","author":"Varela","year":"2020","journal-title":"Commun Biol"},{"issue":"5","key":"10.1016\/j.idc.2023.12.002_bib45","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1513\/AnnalsATS.201812-863OT","article-title":"Developing Inhaled Antibiotics in Cystic Fibrosis: Current Challenges and Opportunities","volume":"16","author":"Nichols","year":"2019","journal-title":"Ann Am Thorac Soc"},{"issue":"3","key":"10.1016\/j.idc.2023.12.002_bib46","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01776-19","article-title":"Phase I, Dose-Escalating Study of the Safety and Pharmacokinetics of Inhaled Dry-Powder Vancomycin (AeroVanc) in Volunteers and Patients with Cystic Fibrosis: a New Approach to Therapy for Methicillin-Resistant Staphylococcus aureus","volume":"64","author":"Waterer","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.idc.2023.12.002_bib47","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.jcf.2018.07.005","article-title":"Eradication of persistent methicillin-resistant Staphylococcus aureus infection in cystic fibrosis","volume":"18","author":"Dezube","year":"2019","journal-title":"Journal of Cystic Fibrosis"},{"issue":"4","key":"10.1016\/j.idc.2023.12.002_bib48","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.jcf.2015.12.004","article-title":"A\u00a0phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patients","volume":"15","author":"Flume","year":"2016","journal-title":"J\u00a0Cyst Fibros"},{"issue":"5","key":"10.1016\/j.idc.2023.12.002_bib50","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.jcf.2019.05.013","article-title":"Clofazimine inhalation suspension for the aerosol treatment of pulmonary nontuberculous mycobacterial infections","volume":"18","author":"Banaschewski","year":"2019","journal-title":"J\u00a0Cyst Fibros"},{"issue":"3","key":"10.1016\/j.idc.2023.12.002_bib51","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1097\/MCP.0000000000000665","article-title":"Beyond antibiotics for pulmonary nontuberculous mycobacterial disease","volume":"26","author":"Waterer","year":"2020","journal-title":"Curr Opin Pulm Med"},{"issue":"3","key":"10.1016\/j.idc.2023.12.002_bib52","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.it.2015.01.003","article-title":"Nitric oxide synthase in innate and adaptive immunity: an update","volume":"36","author":"Bogdan","year":"2015","journal-title":"Trends Immunol"},{"issue":"3","key":"10.1016\/j.idc.2023.12.002_bib53","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/(SICI)1096-9896(199803)184:3<323::AID-PATH2>3.0.CO;2-2","article-title":"Lack of inducible nitric oxide synthase in bronchial epithelium: a possible mechanism of susceptibility to infection in cystic fibrosis","volume":"184","author":"Meng","year":"1998","journal-title":"J\u00a0Pathol"},{"issue":"5","key":"10.1016\/j.idc.2023.12.002_bib54","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S1074-7613(03)00114-6","article-title":"Impaired innate host defense causes susceptibility to respiratory virus infections in cystic fibrosis","volume":"18","author":"Zheng","year":"2003","journal-title":"Immunity"},{"issue":"9","key":"10.1016\/j.idc.2023.12.002_bib55","doi-asserted-by":"crossref","DOI":"10.1099\/acmi.0.000154","article-title":"Antibacterial activity of high-dose nitric oxide against pulmonary Mycobacterium abscessus disease","volume":"2","author":"Bogdanovski","year":"2020","journal-title":"Access Microbiol"},{"issue":"10","key":"10.1016\/j.idc.2023.12.002_bib56","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2021-243979","article-title":"Non-nuberculous mycobacteria infection treated with intermittently inhaled high-dose nitric oxide","volume":"14","author":"Goldbart","year":"2021","journal-title":"BMJ Case Rep"},{"issue":"4","key":"10.1016\/j.idc.2023.12.002_bib57","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1097\/INF.0000000000001780","article-title":"Compassionate Nitric Oxide Adjuvant Treatment of Persistent Mycobacterium Infection in Cystic Fibrosis Patients","volume":"37","author":"Yaacoby-Bianu","year":"2018","journal-title":"Pediatr Infect Dis J"},{"issue":"2","key":"10.1016\/j.idc.2023.12.002_bib58","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jcf.2019.05.002","article-title":"Pilot study to test inhaled nitric oxide in cystic fibrosis patients with refractory Mycobacterium abscessus lung infection","volume":"19","author":"Bentur","year":"2020","journal-title":"J\u00a0Cyst Fibros"},{"key":"10.1016\/j.idc.2023.12.002_bib59","unstructured":"Cystic Fibrosis Foundation https:\/\/apps.cff.org\/Trials\/Pipeline\/details\/10122\/Inhaled-Nitric-Oxide-Thiolanox. Accessed July 7, 2022."},{"issue":"4","key":"10.1016\/j.idc.2023.12.002_bib60","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02127-2017","article-title":"Inhaled granulocyte-macrophage colony-stimulating factor for Mycobacterium abscessus in cystic fibrosis","volume":"51","author":"Scott","year":"2018","journal-title":"Eur Respir J"},{"key":"10.1016\/j.idc.2023.12.002_bib61","unstructured":"Cystic Fibrosis Foundation. https:\/\/apps.cff.org\/Trials\/Pipeline\/details\/10165\/Inhaled-Molgramostim. Accessed July 7, 2022."},{"issue":"1","key":"10.1016\/j.idc.2023.12.002_bib62","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1159\/000163609","article-title":"Targeting iron-dependent DNA synthesis with gallium and transferrin-gallium","volume":"59","author":"Chitambar","year":"1991","journal-title":"Pathobiology"},{"issue":"460","key":"10.1016\/j.idc.2023.12.002_bib63","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aat7520","article-title":"Gallium disrupts bacterial iron metabolism and has therapeutic effects in mice and humans with lung infections","volume":"10","author":"Goss","year":"2018","journal-title":"Sci Transl Med"},{"issue":"4","key":"10.1016\/j.idc.2023.12.002_bib64","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1172\/JCI30783","article-title":"The transition metal gallium disrupts Pseudomonas aeruginosa iron metabolism and has antimicrobial and antibiofilm activity","volume":"117","author":"Kaneko","year":"2007","journal-title":"J\u00a0Clin Invest"},{"issue":"8","key":"10.1016\/j.idc.2023.12.002_bib65","doi-asserted-by":"crossref","first-page":"4826","DOI":"10.1128\/AAC.00331-15","article-title":"Gallium Compounds Exhibit Potential as New Therapeutic Agents against Mycobacterium abscessus","volume":"59","author":"Abdalla","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.idc.2023.12.002_bib66","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.chom.2019.01.014","article-title":"Phage Therapy: A Renewed Approach to Combat Antibiotic-Resistant Bacteria","volume":"25","author":"Kortright","year":"2019","journal-title":"Cell Host & Microbe"},{"issue":"1","key":"10.1016\/j.idc.2023.12.002_bib67","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1128\/MMBR.64.1.69-114.2000","article-title":"Virioplankton: viruses in aquatic ecosystems","volume":"64","author":"Wommack","year":"2000","journal-title":"Microbiology and molecular biology reviews : MMBR"},{"issue":"7520","key":"10.1016\/j.idc.2023.12.002_bib68","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nature13786","article-title":"Biogeography and individuality shape function in the human skin metagenome","volume":"514","author":"Oh","year":"2014","journal-title":"Nature"},{"issue":"7304","key":"10.1016\/j.idc.2023.12.002_bib69","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/nature09199","article-title":"Viruses in the faecal microbiota of monozygotic twins and their mothers","volume":"466","author":"Reyes","year":"2010","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.idc.2023.12.002_bib70","doi-asserted-by":"crossref","DOI":"10.1128\/microbiolspec.BAD-0003-2016","article-title":"Bacteriophage Clinical Use as Antibacterial \"Drugs\": Utility and Precedent","volume":"5","author":"Abedon","year":"2017","journal-title":"Microbiol Spectr"},{"issue":"2","key":"10.1016\/j.idc.2023.12.002_bib71","doi-asserted-by":"crossref","DOI":"10.3390\/v11020096","article-title":"The Preclinical and Clinical Progress of Bacteriophages and Their Lytic Enzymes: The Parts are Easier than the Whole","volume":"11","author":"Abdelkader","year":"2019","journal-title":"Viruses"},{"issue":"5","key":"10.1016\/j.idc.2023.12.002_bib72","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/s41591-019-0437-z","article-title":"Engineered bacteriophages for\u00a0treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus","volume":"25","author":"Dedrick","year":"2019","journal-title":"Nat Med"},{"issue":"9","key":"10.1016\/j.idc.2023.12.002_bib73","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1016\/j.clinthera.2020.07.014","article-title":"Phage Therapy in the Resistance Era: Where Do We Stand and Where Are We Going?","volume":"42","author":"Luong","year":"2020","journal-title":"Clinical Therapeutics"},{"issue":"11","key":"10.1016\/j.idc.2023.12.002_bib74","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1093\/cid\/cix184","article-title":"The Lysis of Pathogenic Escherichia coli by Bacteriophages Releases Less Endotoxin Than by \u03b2-Lactams","volume":"64","author":"Dufour","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"Suppl 1","key":"10.1016\/j.idc.2023.12.002_bib75","article-title":"Bacteriophage therapy for infections in CF","volume":"56","author":"Chan","year":"2021","journal-title":"Pediatr Pulmonol"},{"issue":"5","key":"10.1016\/j.idc.2023.12.002_bib76","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.01652-19","article-title":"Resistance Evolution against Phage Combinations Depends on the Timing and Order of Exposure","volume":"10","author":"Wright","year":"2019","journal-title":"mBio"},{"issue":"1554","key":"10.1016\/j.idc.2023.12.002_bib77","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1098\/rspb.2004.2833","article-title":"Reduced fecundity is the cost of cheating in RNA virus phi6","volume":"271","author":"Dennehy","year":"2004","journal-title":"Proc Biol Sci"},{"issue":"5","key":"10.1016\/j.idc.2023.12.002_bib78","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nrmicro2315","article-title":"Bacteriophage resistance mechanisms","volume":"8","author":"Labrie","year":"2010","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.idc.2023.12.002_bib79","doi-asserted-by":"crossref","first-page":"26717","DOI":"10.1038\/srep26717","article-title":"Phage selection restores antibiotic sensitivity in MDR Pseudomonas aeruginosa","volume":"6","author":"Chan","year":"2016","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.idc.2023.12.002_bib80","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1093\/emph\/eoy005","article-title":"Phage treatment of an aortic graft infected with Pseudomonas aeruginosa","volume":"2018","author":"Chan","year":"2018","journal-title":"Evol Med Public Health"},{"issue":"8","key":"10.1016\/j.idc.2023.12.002_bib81","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1038\/s41591-021-01403-9","article-title":"Potent antibody-mediated neutralization limits bacteriophage treatment of a pulmonary Mycobacterium abscessus infection","volume":"27","author":"Dedrick","year":"2021","journal-title":"Nat Med"}],"container-title":["Infectious Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0891552023000880?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0891552023000880?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T15:31:44Z","timestamp":1760196704000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0891552023000880"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":80,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S0891552023000880"],"URL":"https:\/\/doi.org\/10.1016\/j.idc.2023.12.002","relation":{},"ISSN":["0891-5520"],"issn-type":[{"value":"0891-5520","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel Approaches to Multidrug-Resistant Infections in Cystic Fibrosis","name":"articletitle","label":"Article Title"},{"value":"Infectious Disease Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.idc.2023.12.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}